Positive News Coverage Somewhat Unlikely to Affect Orthofix International N.V. (OFIX) Stock Price
Media stories about Orthofix International N.V. (NASDAQ:OFIX) have trended positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Orthofix International N.V. earned a daily sentiment score of 0.28 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 48.5960553845628 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- ETFs with exposure to Orthofix International NV : November 2, 2017 (finance.yahoo.com)
- Orthofix International N.V. (OFIX) to Post FY2017 Earnings of $1.60 Per Share, Gabelli Forecasts (americanbankingnews.com)
- Orthofix International NV :OFIX-US: Earnings Analysis: Q3, 2017 By the Numbers : November 1, 2017 (finance.yahoo.com)
- FY2017 EPS Estimates for Orthofix International N.V. (OFIX) Raised by Jefferies Group (americanbankingnews.com)
- Orthofix International Reports Third Quarter 2017 Financial Results (finance.yahoo.com)
Several equities analysts have recently issued reports on the company. Jefferies Group LLC reiterated a “buy” rating and issued a $55.00 price target (up previously from $50.00) on shares of Orthofix International N.V. in a research note on Thursday, August 10th. Zacks Investment Research upgraded Orthofix International N.V. from a “hold” rating to a “buy” rating and set a $60.00 price target on the stock in a research note on Thursday. BidaskClub lowered Orthofix International N.V. from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, July 25th. TheStreet lowered Orthofix International N.V. from a “b” rating to a “c+” rating in a research note on Tuesday, October 31st. Finally, BTIG Research set a $56.00 price target on Orthofix International N.V. and gave the company a “buy” rating in a research note on Monday, October 30th. Seven investment analysts have rated the stock with a buy rating, Orthofix International N.V. has an average rating of “Buy” and a consensus price target of $54.42.
Orthofix International N.V. (NASDAQ:OFIX) traded up $0.73 during midday trading on Friday, hitting $51.89. The company’s stock had a trading volume of 314,587 shares, compared to its average volume of 150,646. Orthofix International N.V. has a 1 year low of $32.51 and a 1 year high of $54.33. The company has a market cap of $942.84, a price-to-earnings ratio of 33.92, a PEG ratio of 2.61 and a beta of 0.15.
Orthofix International N.V. (NASDAQ:OFIX) last released its quarterly earnings results on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.41 by $0.01. Orthofix International N.V. had a return on equity of 10.26% and a net margin of 0.33%. The firm had revenue of $105.30 million for the quarter, compared to analyst estimates of $100.67 million. During the same quarter in the previous year, the company posted $0.36 EPS. The business’s revenue was up 6.9% on a year-over-year basis. equities analysts expect that Orthofix International N.V. will post 1.61 earnings per share for the current year.
In related news, CFO Rice Doug sold 7,353 shares of the company’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $49.46, for a total transaction of $363,679.38. Following the transaction, the chief financial officer now directly owns 44,743 shares of the company’s stock, valued at approximately $2,212,988.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Brad Mason sold 2,733 shares of the company’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $48.10, for a total value of $131,457.30. Following the transaction, the chief executive officer now directly owns 188,053 shares in the company, valued at $9,045,349.30. The disclosure for this sale can be found here. Insiders sold a total of 23,406 shares of company stock worth $1,138,531 over the last three months. 5.60% of the stock is owned by company insiders.
TRADEMARK VIOLATION WARNING: This piece of content was first posted by Watch List News and is owned by of Watch List News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/positive-news-coverage-somewhat-unlikely-to-affect-orthofix-international-n-v-ofix-stock-price/1680867.html.
Orthofix International N.V. Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.